Pharvaris (PHVS) to Release Quarterly Earnings on Wednesday

Pharvaris (NASDAQ:PHVS) is expected to announce its Q3 2025 results before the market opens on Wednesday, November 12th. Analysts expect the company to announce earnings of ($0.80) per share for the quarter. Investors can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Wednesday, November 12, 2025 at 4:00 PM ET.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.94) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.07). On average, analysts expect Pharvaris to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Pharvaris Price Performance

Shares of Pharvaris stock opened at $21.64 on Wednesday. Pharvaris has a 1 year low of $11.51 and a 1 year high of $26.33. The firm has a market cap of $1.13 billion, a PE ratio of -6.44 and a beta of -2.78. The stock has a fifty day moving average price of $23.07 and a 200-day moving average price of $20.30.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. boosted its stake in Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after purchasing an additional 783 shares during the period. Legal & General Group Plc boosted its stake in Pharvaris by 17.2% in the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after purchasing an additional 1,695 shares during the period. California State Teachers Retirement System boosted its stake in Pharvaris by 9.8% in the 2nd quarter. California State Teachers Retirement System now owns 14,048 shares of the company’s stock worth $247,000 after purchasing an additional 1,257 shares during the period. Boothbay Fund Management LLC bought a new position in Pharvaris in the 2nd quarter worth about $285,000. Finally, Amundi boosted its stake in Pharvaris by 2,741,600.0% in the 2nd quarter. Amundi now owns 27,417 shares of the company’s stock worth $489,000 after purchasing an additional 27,416 shares during the period.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on PHVS. Bank of America raised Pharvaris from an “underperform” rating to a “neutral” rating and raised their target price for the company from $16.00 to $27.00 in a research report on Thursday, October 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research report on Wednesday, October 8th. HC Wainwright began coverage on Pharvaris in a research report on Wednesday, October 15th. They set a “buy” rating and a $60.00 target price for the company. JMP Securities decreased their target price on Pharvaris from $55.00 to $52.00 and set a “market outperform” rating for the company in a research report on Wednesday, August 13th. Finally, Zacks Research upgraded Pharvaris from a “strong sell” rating to a “hold” rating in a research note on Monday, August 18th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.17.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.